Fusobacterium nucleatum and Colorectal Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Dahan L, Sadok A, Formento JL, et al. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–620. doi:10.1111/j.1476-5381.2009.00341.x
   PubMed Web of Science ®Google Scholar
• International Mismatch Repair Consortium. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol. 2021;22(7):1014–1022. doi:10.1016/S1470-2045(21)00189-3
   Web of Science ®Google Scholar
• Macaron C, Mankaney GN, Haider M, et al. Chemoprevention considerations in patients with hereditary colorectal cancer syndromes. Gastrointest Endosc Clin N Am. 2022;32(1):131–146. doi:10.1016/j.giec.2021.08.005
   Google Scholar
• Qin X, Liu CY, Xiong YL, et al. The clinical features of chronic intestinal schistosomiasis-related intestinal lesions. BMC Gastroenterol. 2021;21(1):12. doi:10.1186/s12876-020-01591-7
   Web of Science ®Google Scholar
• Vernia F, Longo S, Stefanelli G, et al. Dietary factors modulating colorectal carcinogenesis. Nutrients. 2021;13(1):143. doi:10.3390/nu13010143
   PubMed Web of Science ®Google Scholar
• Osman MA, Neoh HM, Ab Mutalib NS, et al. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci Rep. 2021;11(1):2925. doi:10.1038/s41598-021-82465-0
   PubMed Web of Science ®Google Scholar
• Shariati A, Razavi S, Ghaznavi-Rad E, et al. Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: a preliminary study. Infect Agent Cancer. 2021;16(1):41. doi:10.1186/s13027-021-00381-4
   Web of Science ®Google Scholar
• Chen S, Su T, Zhang Y, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes. 2020;11(3):511–525. doi:10.1080/19490976.2019.1695494
   PubMed Web of Science ®Google Scholar
• Lee JB, Kim KA, Cho HY, et al. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Sci Rep. 2021;11(1):20263. doi:10.1038/s41598-021-98941-6
   PubMed Web of Science ®Google Scholar
• Liu Y, Baba Y, Ishimoto T, et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021;124(5):963–974. doi:10.1038/s41416-020-01198-5
   PubMed Web of Science ®Google Scholar
• Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381–1390.
   PubMed Web of Science ®Google Scholar
• Lee DW, Han SW, Kang JK, et al. Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–3395. doi:10.1245/s10434-018-6681-5
   PubMed Web of Science ®Google Scholar
• Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016;22(11):3227–3233. doi:10.3748/wjg.v22.i11.3227
   PubMed Web of Science ®Google Scholar
• Suehiro Y, Sakai K, Nishioka M, et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem. 2017;54(1):86–91. doi:10.1177/0004563216643970
   PubMed Web of Science ®Google Scholar
• Leung PHM, Subramanya R, Mou Q, et al. Characterization of mucosa-associated microbiota in matched cancer and non-neoplastic mucosa from patients with colorectal cancer. Front Microbiol. 2019;10:1317. doi:10.3389/fmicb.2019.01317
   PubMed Web of Science ®Google Scholar
• Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–661. doi:10.1001/jamaoncol.2015.1377
   PubMed Web of Science ®Google Scholar
• Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016;22(2):557–566. doi:10.3748/wjg.v22.i2.557
   PubMed Web of Science ®Google Scholar
• Tesi RJ. MDSC; the most important cell you have never heard of. Trends Pharmacol Sci. 2019;40(1):4–7. doi:10.1016/j.tips.2018.10.008
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. doi:10.1016/j.chom.2013.07.007
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Najafi M, Hashemi Goradel N, Farhood B, et al. Macrophage polarity in cancer: a review. J Cell Biochem. 2019;120(3):2756–2765. doi:10.1002/jcb.27646
   PubMed Web of Science ®Google Scholar
• Chen T, Li Q, Wu J, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother. 2018;67(10):1635–1646. doi:10.1007/s00262-018-2233-x
   PubMed Web of Science ®Google Scholar
• Hu L, Liu Y, Kong X, et al. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S100A9 cascade. Front Immunol. 2021;12:658681. doi:10.3389/fimmu.2021.658681
   PubMed Web of Science ®Google Scholar
• Park HE, Kim JH, Cho NY, Lee HS, Kang GH. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471(3):329–336. doi:10.1007/s00428-017-2171-6
   Web of Science ®Google Scholar
• Saito T, Nishikawa H, Wada H, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679–684. doi:10.1038/nm.4086
   PubMed Web of Science ®Google Scholar
• Ono M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology. 2020;160(4):393. doi:10.1111/imm.13178
   Web of Science ®Google Scholar
• Dong X, Pan P, Zheng DW, et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. Sci Adv. 2020;6(20):eaba1590. doi:10.1126/sciadv.aba1590
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim BK, Park SJ, Kim JH. Impact of Fusobacterium nucleatum in the gastrointestinal tract on natural killer cells. World J Gastroenterol. 2021;27(29):4879–4889. doi:10.3748/wjg.v27.i29.4879
   PubMed Web of Science ®Google Scholar
• Fathi M, Pustokhina I, Kuznetsov SV, et al. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life. 2021;73(5):726–738. doi:10.1002/iub.2461
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.010
   PubMed Web of Science ®Google Scholar
• Dabija-Wolter G, Cimpan MR, Costea DE, et al. Fusobacterium nucleatum enters normal human oral fibroblasts in vitro. J Periodontol. 2009;80(7):1174–1183. doi:10.1902/jop.2009.090051
   Web of Science ®Google Scholar
• Kashani N, Bezmin Abadi AT, Rahimi F, Forootan M. FadA-positive Fusobacterium nucleatum is prevalent in biopsy specimens of Iranian patients with colorectal cancer. New Microbes New Infect. 2020;34:100651. doi:10.1016/j.nmni.2020.100651
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206. doi:10.1016/j.chom.2013.07.012
   PubMed Web of Science ®Google Scholar
• Guo P, Tian Z, Kong X, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39(1):202. doi:10.1186/s13046-020-01677-w
   PubMed Web of Science ®Google Scholar
• Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275(5307):1787–1790. doi:10.1126/science.275.5307.1787
   PubMed Web of Science ®Google Scholar
• Dadashi M, Hajikhani B, Faghihloo E, et al. Proliferative effect of FadA recombinant protein from Fusobacterium nucleatum on SW480 colorectal cancer cell line. Infect Disord Drug Targets. 2021;21(4):623–628. doi:10.2174/1871526520666200720113004
   PubMedGoogle Scholar
• Ganesan K, Guo S, Fayyaz S, Zhang G, Xu B. Targeting programmed Fusobacterium nucleatum Fap2 for colorectal cancer therapy. Cancers. 2019;11(10):1592. doi:10.3390/cancers11101592
   Web of Science ®Google Scholar
• Abed J, Emgård JE, Zamir G, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20(2):215–225. doi:10.1016/j.chom.2016.07.006
   PubMed Web of Science ®Google Scholar
• Abed J, Maalouf N, Parhi L, et al. Tumor targeting by Fusobacterium nucleatum: a pilot study and future perspectives. Front Cell Infect Microbiol. 2017;7:295. doi:10.3389/fcimb.2017.00295
   PubMed Web of Science ®Google Scholar
• Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259. doi:10.1038/s41467-020-16967-2
   PubMed Web of Science ®Google Scholar
• Santaolalla R, Sussman DA, Ruiz JR, et al. TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One. 2013;8(5):e63298. doi:10.1371/journal.pone.0063298
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu J, Chen T, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis in mice via a toll-like receptor 4/p21-activated kinase 1 cascade. Dig Dis Sci. 2018;63(5):1210–1218. doi:10.1007/s10620-018-4999-2
   PubMed Web of Science ®Google Scholar
• Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137(6):1258–1268.
   PubMed Web of Science ®Google Scholar
• Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21. Gastroenterology. 2017;152(4):851–866.e24. doi:10.1053/j.gastro.2016.11.018
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16. doi:10.1016/j.cell.2017.07.008
   PubMed Web of Science ®Google Scholar
• Kędziora A, Lesiów MK, Krupa K, et al. Protocol of proceedings with Fusobacterium nucleatum and optimization of ABTS method for detection of reactive oxygen species. Future Microbiol. 2020;15:259–271. doi:10.2217/fmb-2019-0010
   Web of Science ®Google Scholar
• Tada A, Nakayama-Imaohji H, Yamasaki H, et al. Effect of thymoquinone on Fusobacterium nucleatum-associated biofilm and inflammation. Mol Med Rep. 2020;22(2):643–650. doi:10.3892/mmr.2020.11136
   Web of Science ®Google Scholar
• Okita Y, Koi M, Takeda K, et al. Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. Gut Pathog. 2020;12(1):46. doi:10.1186/s13099-020-00384-3
   PubMed Web of Science ®Google Scholar
• Koi M, Okita Y, Carethers JM. Fusobacterium nucleatum infection in colorectal cancer: linking inflammation, DNA mismatch repair and genetic and epigenetic alterations. J Anus Rectum Colon. 2018;2(2):37–46. doi:10.23922/jarc.2017-055
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-310101
   PubMed Web of Science ®Google Scholar
• Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype. Mol Cell. 2014;55(6):904–915. doi:10.1016/j.molcel.2014.08.010
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306. doi:10.1101/gr.126516.111
   PubMed Web of Science ®Google Scholar
• Shang FM, Liu HL. Fusobacterium nucleatum and colorectal cancer: a review. World J Gastrointest Oncol. 2018;10(3):71–81. doi:10.4251/wjgo.v10.i3.71
   PubMed Web of Science ®Google Scholar